However, one patient acquired the mutation FLT3-ITD and another RUNX1 + del (7q) at first relapse, while the relapsed AML cells of one patient no longer contained the abnormalities (FLT3-TDK, IDH2, BCOR) present at the time of first diagnosis (Table S1). This evidence concerns the gene BCOR and acute myeloid leukemia.